Payment overview · 2025
General Payments
$696.36
37 reported records · 14 companies
Healthcare provider profile · identity verified
Christopher L Kafka, DO
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1629016704
Verified facts
What the public records show
CMS Open Payments records show Christopher L Kafka, DO received $696.36 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.42 | 25.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $173.73 | 24.9% | 14 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $55.97 | 8.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.06 | 7.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.13 | 6.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.06 | 6.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.12 | 4.0% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $22.87 | 3.3% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $21.74 | 3.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.52 | 2.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.82 | 2.4% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $16.01 | 2.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.92 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.99 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $696.36 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $179.42 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $168.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $168.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $128.98 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $127.83 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $55.97 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.13 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.13 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $28.12 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $11.90 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $9.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $9.80 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 33 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 148 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
148 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 932 | 279 |
| Lisinopril | Lisinopril | 525 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 435 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 115 |
| Omeprazole | Omeprazole | 285 | 78 |
| Gabapentin | Gabapentin | 241 | 97 |
| Losartan Potassium | Losartan Potassium | 239 | 65 |
| Meloxicam | Meloxicam | 237 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 65 |
| Carvedilol | Carvedilol | 213 | 66 |
| Metformin Hcl | Metformin Hcl | 189 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 56 |
| Alprazolam | Alprazolam | 183 | 46 |
| Simvastatin | Simvastatin | 183 | 48 |
| Glimepiride | Glimepiride | 178 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 53 |
| Mounjaro | Tirzepatide | 148 | 28 |
| Famotidine | Famotidine | 145 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 44 |
| Tramadol Hcl | Tramadol Hcl | 132 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 40 |
| Metformin Hcl Er | Metformin Hcl | 128 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 36 |
| Jardiance | Empagliflozin | 124 | 36 |
| Celecoxib | Celecoxib | 121 | 46 |
| Azithromycin | Azithromycin | 120 | 110 |
| Trazodone Hcl | Trazodone Hcl | 118 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 36 |
| Allopurinol | Allopurinol | 105 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 40 |
| Furosemide | Furosemide | 101 | 37 |
| Bupropion Xl | Bupropion Hcl | 98 | 30 |
| Pregabalin | Pregabalin | 88 | 29 |
| Potassium Chloride | Potassium Chloride | 84 | 38 |
| Eliquis | Apixaban | 78 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 31 |
| Sertraline Hcl | Sertraline Hcl | 68 | 22 |
| Ezetimibe | Ezetimibe | 67 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 23 |
| Methylprednisolone | Methylprednisolone | 63 | 56 |
| Spironolactone | Spironolactone | 61 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 41 |
| Ibandronate Sodium | Ibandronate Sodium | 59 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 19 |
| Valsartan | Valsartan | 57 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 55 | 14 |
| Warfarin Sodium | Warfarin Sodium | 55 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 23 |
| Montelukast Sodium | Montelukast Sodium | 49 | 17 |
| Mirtazapine | Mirtazapine | 48 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 38 |
| Ozempic | Semaglutide | 48 | 14 |
| Memantine Hcl | Memantine Hcl | 47 | 16 |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Cefdinir | Cefdinir | 42 | 36 |
| Finasteride | Finasteride | 42 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 14 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Atenolol | Atenolol | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 33 | 33 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 14 |
| Lorazepam | Lorazepam | 30 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | 11 |
| Cephalexin | Cephalexin | 28 | 26 |
| Topiramate | Topiramate | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 17 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 18 |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Zaleplon | Zaleplon | 15 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | 11 |
| Hysingla Er | Hydrocodone Bitartrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Nitroglycerin | Nitroglycerin | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $696.36 · 37 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CRYSVITA, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, INSPIRE, JARDIANCE, JOURNAVX, KISUNLA, MOUNJARO, OFEV, OTEZLA, Omnipod, Paradise Ultrasound Renal Denervation System, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error